Dr Cheryl Lee Barton: Biography
Dr Cheryl Lee Barton graduated from Queen's University Belfast in 1993 with a doctorate from the department of Biochemistry and Biology. This three year project involved in the characterization of novel proteins in parasites and hosts as potential targets for drug development. During this period, Cheryl was offered a sabbatical at Merck Sharp and Dohme's Neuroscience centre in Harlow, Essex, UK, to develop assays for protein identification.
It was the success of this placement which lead Merck to offer Dr Barton a two year post-doctorate and later a permanent position which after seven years saw Cheryl managing a specialist team of biochemists and behavioural pharmacologists who became responsible for evaluating safety assessment candidates in pre-clinical drug development. The primary projects ranged from Alzheimer's disease to Stroke and latterly Depression to Schizophrenia.
In 1999, Dr Barton was head hunted away from Industry into the Dutch Investment Bank ABN Amro N.V to join their team of pharmaceutical researchers as a senior equity analyst in London. Whilst their, Cheryl became the lead analyst on AstraZeneca, Roche and Sanofi-Synthelabo and was responsible for writing thematic research notes, evaluating new drugs in development and assessing their potential impact on Pan-European stocks.
In 2002, Dr Barton established the consultancy www.PharmaVision.co.uk to provide independent, tailor made, pharmaceutical thematic research to Investment Houses, competitive intelligence specialists and pharmaceutical companies. The research reports combine independent scientific analysis with patient based models to forecast the potential sales growth of key drugs in clinical development.
